Similar articles

• ["Therapeutic drug monitoring", a strategy for improving drug safety in child and adolescent psychiatry and psychotherapy].

  Gerlach M, Schulz E, Fegert JM. Gerlach M, et al. Z Kinder Jugendpsychiatr Psychother. 2005 Jul;33(3):157-8. doi: 10.1024/1422-4917.33.3.157. Z Kinder Jugendpsychiatr Psychother. 2005. PMID: 16097263 German. No abstract available.
• Practical clinical issues regarding child and adolescent psychopharmacology.

  Kutcher S. Kutcher S. Child Adolesc Psychiatr Clin N Am. 2000 Jan;9(1):245-60. Child Adolesc Psychiatr Clin N Am. 2000. PMID: 10674199 Review.
• [Off-label use of drugs in psychiatry and neurology].

  Wallesch CW. Wallesch CW. Fortschr Neurol Psychiatr. 2004 May;72(5):243-4. doi: 10.1055/s-2003-812452. Fortschr Neurol Psychiatr. 2004. PMID: 15136944 German. No abstract available.
• Therapeutic drug monitoring. Principles and practice.

  Preskorn SH, Burke MJ, Fast GA. Preskorn SH, et al. Psychiatr Clin North Am. 1993 Sep;16(3):611-45. Psychiatr Clin North Am. 1993. PMID: 8415237 Review.
• [Possibilities of concomitant drug treatment of stuttering in childhood and adolescence].

  Marcus A, Schmidt MH. Marcus A, et al. Z Kinder Jugendpsychiatr. 1995 Sep;23(3):182-94. Z Kinder Jugendpsychiatr. 1995. PMID: 7571877 Review. German. No abstract available.